Aethlon Medical, Inc. (AEMD): Price and Financial Metrics
AEMD Price/Volume Stats
Current price | $1.67 | 52-week high | $7.20 |
Prev. close | $1.73 | 52-week low | $1.40 |
Day low | $1.63 | Volume | 10,800 |
Day high | $1.72 | Avg. volume | 7,819 |
50-day MA | $1.79 | Dividend yield | N/A |
200-day MA | $2.43 | Market Cap | 4.38M |
AEMD Stock Price Chart Interactive Chart >
AEMD Stock Summary
- AETHLON MEDICAL INC's market capitalization of $5,409,610 is ahead of just 2.81% of US-listed equities.
- As for revenue growth, note that AEMD's revenue has grown 1,799.4% over the past 12 months; that beats the revenue growth of 99.6% of US companies in our set.
- The volatility of AETHLON MEDICAL INC's share price is greater than that of 97.57% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to AEMD, based on their financial statements, market capitalization, and price volatility, are GEVO, SAFE, FATH, NE, and CNX.
- AEMD's SEC filings can be seen here. And to visit AETHLON MEDICAL INC's official web site, go to www.aethlonmedical.com.
AEMD Valuation Summary
- AEMD's EV/EBIT ratio is 0.3; this is 97.95% lower than that of the median Healthcare stock.
- AEMD's EV/EBIT ratio has moved up 10.9 over the prior 103 months.
Below are key valuation metrics over time for AEMD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
AEMD | 2023-12-29 | 9.6 | 0.5 | -0.5 | 0.3 |
AEMD | 2023-12-28 | 9.4 | 0.5 | -0.5 | 0.4 |
AEMD | 2023-12-27 | 9.1 | 0.5 | -0.4 | 0.4 |
AEMD | 2023-12-26 | 8.4 | 0.5 | -0.4 | 0.4 |
AEMD | 2023-12-22 | 8.2 | 0.5 | -0.4 | 0.4 |
AEMD | 2023-12-21 | 8.2 | 0.5 | -0.4 | 0.4 |
AEMD Growth Metrics
- Its 4 year price growth rate is now at -93.28%.
- The year over year net cashflow from operations growth rate now stands at -44.38%.
- Its 2 year net income to common stockholders growth rate is now at -63.42%.
The table below shows AEMD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 0.013116 | -10.65749 | -13.34793 |
2022-09-30 | 0.030233 | -11.42449 | -13.02391 |
2022-06-30 | 0.162199 | -10.42425 | -11.22446 |
2022-03-31 | 0.294165 | -9.767157 | -10.41609 |
2021-12-31 | 0.315282 | -8.90671 | -8.893984 |
2021-09-30 | 0.923036 | -8.386 | -8.811144 |
AEMD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AEMD has a Quality Grade of D, ranking ahead of 11.25% of graded US stocks.
- AEMD's asset turnover comes in at 0.049 -- ranking 72nd of 75 Measuring and Control Equipment stocks.
- FCUV, SYPR, and SENS are the stocks whose asset turnover ratios are most correlated with AEMD.
The table below shows AEMD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.049 | 1 | 11.337 |
2021-03-31 | 0.048 | 1 | 10.363 |
2020-12-31 | 0.061 | 1 | 11.087 |
2020-09-30 | 0.053 | 1 | 11.287 |
2020-06-30 | 0.076 | 1 | 13.238 |
2020-03-31 | 0.135 | 1 | 15.993 |
AEMD Price Target
For more insight on analysts targets of AEMD, see our AEMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $9.33 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Aethlon Medical, Inc. (AEMD) Company Bio
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.
Latest AEMD News From Around the Web
Below are the latest news stories about AETHLON MEDICAL INC that investors may wish to consider to help them evaluate AEMD as an investment opportunity.
AEMD: Expect Focus on Oncology Studies; Cost Containment EffortsBy M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 & knows the company well, in our view. |
Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call TranscriptAethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript November 14, 2023 Operator: Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2024 Earnings and Corporate Update Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Mr. Michael Miller with Rx Communications. […] |
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate UpdateAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2023 and provided an update on recent developments. |
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating OfficerAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that James B. Frakes, M.B.A., Chief Financial Officer of the Company, was appointed as Interim Chief Executive Officer, replacing Charles J. Fisher, Jr. M.D. Mr. Frakes also was appointed as a member of the Board of Directors and will remain as Chief Financial Officer of the Company. Additionally, Guy Cipriani, formerly Chief |
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023. |
AEMD Price Returns
1-mo | 0.00% |
3-mo | -11.17% |
6-mo | -28.94% |
1-year | -54.46% |
3-year | -92.23% |
5-year | -98.88% |
YTD | -23.74% |
2023 | -20.48% |
2022 | -85.19% |
2021 | -24.70% |
2020 | 156.49% |
2019 | -96.13% |
Continue Researching AEMD
Want to do more research on Aethlon Medical Inc's stock and its price? Try the links below:Aethlon Medical Inc (AEMD) Stock Price | Nasdaq
Aethlon Medical Inc (AEMD) Stock Quote, History and News - Yahoo Finance
Aethlon Medical Inc (AEMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...